Central venous catheters consist of a long, thin tube that is inserted into a large vein to deliver medication, nutrition, intravenous fluids, and cancer medications. Different types of central venous catheters can be utilized by patients according to the duration of the treatment. These include, tunneled central venous catheters (CVC) and implanted ports for long term use, peripherally inserted central catheter (PICC) for intermediate term, and non-tunneled CVC for short term use. Central venous catheterization is used for chemotherapy administration, total parenteral nutrition, administration of intravenous fluids and blood, platelet transfusions, and other applications.

Market Dynamics

Increasing prevalence of renal diseases is a major factor driving the central venous catheter market growth. According to the National Center for Chronic Disease Prevention and Health Promotion, 2017, around 30 million people or 15% of the U.S. adults were estimated to have chronic kidney.

Moreover, introduction of innovative products and increasing requirement of long-duration IV therapies such as chemotherapy is expected to boost the market growth. For instance, in May, 2018, Pursuit Vascular, Inc., received the U.S. Food and Drug Administration (FDA) clearance for a broader indication of its ClearGuard HD caps to include reduction in the incidence of central-line associated bloodstream infection (CLABSI) in hemodialysis patients with central venous catheters (CVCs).

Increasing prevalence of cancer is expected to propel growth of the central venous catheter market

Cancer is a class of chronic disease that is characterized by out-of-controlled growth of cells. According to The National Cancer Institute, 2013, there are over 100 different types of cancer that can be described from the type of cells they are formed from. According to the American Cancer Society, 2017, cancer is the second most common cause of death in the U.S., which accounts for nearly 1 out of every 4 deaths.

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/2610

According to the National Center for Chronic Disease Prevention and Health Promotion, 2017, around 30 million people or 15% of the U.S. adults were estimated to have chronic kidney.

According to the World Health Organization (WHO), 2012, cancer is the second leading cause of morbidity and mortality worldwide, with around 14 million new cases registered in 2012. Furthermore, WHO stated that the number of new cases is expected to increase by around 70% by 2030. In 2015, cancer was responsible for 8.8 million deaths worldwide.

Increasing collaboration strategies adopted by market players is expected to bolster growth of the U.S. central venous catheter market

The U.S. central venous catheter market is expected to witness significant growth due to increasing adoption of collaboration strategies by market players. For instance, in 2017, Becton, Dickinson, and Company acquired C.R. Bard, Inc. which created a new health care industry leader with approximately US$ 16 billion in annualized revenue. Similarly, in July 2018, B.Braun Melsungen AG acquired the bloodlines business of NxStage Medical, Inc. This acquisition helped dialysis business of B. Braun Melsungen AG.

Key Players

Major players operating in the U.S. central venous catheter market include, AngioDynamics, Inc., C. R. Bard, Inc., Teleflex Incorporated, B. Braun Melsungen AG, Medtronic Plc., Vygon Ltd., Cook Medical, Inc., Argon Medical Devices, Inc., ICU Medical, Inc., and Theragenics Corporation.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]